about
Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosaEstimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusionVirus neutralisation: new insights from kinetic neutralisation curvesAnalysis of the subunit stoichiometries in viral entry.Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasionPredicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entryInteraction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in MucusMolecular determinants of the ratio of inert to infectious virus particles.Dense Array of Spikes on HIV-1 Virion Particles.Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsNeutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.Mathematical model of multivalent virus-antibody complex formation in humans following acute and chronic HIV infections.How do antigenically varying pathogens avoid cross-reactive responses to invariant antigens?Estimating treatment prolongation for persistent infections
P2860
Q27322437-A2989E33-20BC-4084-A2B4-F25FE2F6574AQ28478341-6C774F5B-C026-4CED-A3D3-5E3712015055Q28487427-A1D65DA8-EBEF-4843-92B7-8EC3711C0A5DQ31053897-2943C4FB-7BAC-47B8-8ACD-C5FA6685D767Q31151010-F8760E87-C738-4ADA-9B5E-1C3393A47202Q33595754-E103F6EE-FCE5-4747-86F9-79E1A977BAE3Q33638320-C5EE783E-8AA7-4A94-BDD4-081BFDBDB108Q34875765-0CE117FF-F595-4E9B-85CF-7EF194E389B5Q35102328-C1A501BC-4040-4BC6-A37B-BB22436BB71BQ35647772-60DFCA2A-5C64-404F-B390-EF09CAB8C10EQ36298503-7E9710CA-42B5-4B6F-BC87-8DB1F7A20967Q36450159-6E28E9B6-9578-44B9-976A-3596320DEC0DQ36494676-E267457C-6825-40E5-BEFD-1C4EBF50726EQ38817990-F02ABEF1-9FE4-4B85-B59D-785F8809E837Q38989507-6C8506BE-5A49-4DBA-9A9C-35A637D29026Q39454698-BA6C1364-7ED2-4118-9FE4-036CCEB02A84Q40295939-9573C2FC-D6E1-4DD0-8200-1D4FCD257656Q41752911-DB06AB26-5FE1-40C2-BEA9-4B7BAA14465EQ51396948-8FEC7E27-C9BF-43CE-ABD7-F52B01E10FBAQ58792186-18A6D531-67AB-42B8-8F2E-E1BB20CEEFF4
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Estimating the stoichiometry of HIV neutralization.
@ast
Estimating the stoichiometry of HIV neutralization.
@en
Estimating the stoichiometry of HIV neutralization.
@nl
type
label
Estimating the stoichiometry of HIV neutralization.
@ast
Estimating the stoichiometry of HIV neutralization.
@en
Estimating the stoichiometry of HIV neutralization.
@nl
prefLabel
Estimating the stoichiometry of HIV neutralization.
@ast
Estimating the stoichiometry of HIV neutralization.
@en
Estimating the stoichiometry of HIV neutralization.
@nl
P2860
P1476
Estimating the stoichiometry of HIV neutralization.
@en
P2093
Roland R Regoes
P2860
P304
P356
10.1371/JOURNAL.PCBI.1000713
P577
2010-03-19T00:00:00Z